Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded.
Recommended Working Concentration: 0.05-1 μg/ml
Summary
Specifications
Antibody Isotype
IgG
Immunogen
Ranibizumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. Recommended Working Concentration: 0.05-1 μg/ml
General Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity.
Target
Alternative Names
Mouse monoclonal antibody to Lucentis; Lucentis; Ranibizumab; rhuFab V2; UNII-ZL1R02VT79
Citations
Publication ()
Have you cited CABT-ZB274 in a publication? Let us know and earn a reward for your research.
My Review for Rabbit Anti-Ranibizumab polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
